Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2/3，multicenter and single-arm clinical trial of Camrelizumab
plus decitabine for Anti-PD-1 treatment-naive patients with relapsed or refractory Hodgkin
Lymphoma. The primary objective of this study is to evaluate the long-term response duration
with Camrelizumab plus decitabine in relapsed or refractory Hodgkin Lymphoma.